Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Kyverna Therapeutics, Inc. - Common Stock
(NQ:
KYTX
)
6.850
+0.030 (+0.44%)
Streaming Delayed Price
Updated: 12:37 PM EDT, Sep 29, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
460,855
Open
6.830
Bid (Size)
6.840 (300)
Ask (Size)
6.860 (800)
Prev. Close
6.820
Today's Range
6.750 - 6.949
52wk Range
5.300 - 13.67
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
September 24, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics to Present at Upcoming Investor Conferences
September 02, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
-21.9%
-21.9%
1 Month
-19.2%
-19.2%
3 Month
-22.0%
-22.0%
6 Month
-9.6%
-9.6%
1 Year
+15.3%
+15.3%
More News
Read More
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
August 11, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
July 27, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
June 22, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
↗
June 08, 2026
Via
The Motley Fool
Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
June 03, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
May 18, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics to Present at Upcoming Investor Conferences
May 14, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
May 12, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
May 04, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Which stocks are moving before the opening bell on Wednesday?
↗
April 22, 2026
Via
Chartmill
Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
↗
April 22, 2026
Via
Benzinga
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
April 21, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
April 20, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
April 09, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
March 26, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026
March 05, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences
March 03, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
February 24, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
February 03, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference
January 12, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference
January 05, 2026
From
Kyverna Therapeutics, Inc.
Via
GlobeNewswire
On Thursday, there are stocks with unusual volume. Let's take a look.
↗
December 18, 2025
Via
Chartmill
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
↗
December 17, 2025
Via
Chartmill
Frequently Asked Questions
Is Kyverna Therapeutics, Inc. - Common Stock publicly traded?
Yes, Kyverna Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Kyverna Therapeutics, Inc. - Common Stock trade on?
Kyverna Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Kyverna Therapeutics, Inc. - Common Stock?
The ticker symbol for Kyverna Therapeutics, Inc. - Common Stock is KYTX on the Nasdaq Stock Market
What is the current price of Kyverna Therapeutics, Inc. - Common Stock?
The current price of Kyverna Therapeutics, Inc. - Common Stock is 6.850
When was Kyverna Therapeutics, Inc. - Common Stock last traded?
The last trade of Kyverna Therapeutics, Inc. - Common Stock was at 09/29/26 12:37 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
